H

Current Clinical Trials

Hematologic Oncology, Hematological, Bleeding & Thrombotic Disorders research

To inquire about benign or malignant hematology ongoing clinical trials, please reach the clinical research team on 01-350000 Ext: 5110,  7804 or 7803

For trials involving Dr. Bazarbachi please reach Ext: 7090/1

For international clinical trials on malignant hematology or blood cancers, please check the following link: https://clinicaltrials.gov/

Ongoing Benign Hematology clinical trials:

 PI: Dr. Ali Taher

• VIT-2763-SCD 202/BIO-2021-0171: A Phase 2a, double-blind, randomized, placebo-controlled, ascending dose and maintenance dose, efficacy, and safety study of multiple doses of VIT-2763 in subjects with sickle cell disease (VIFOR SCD)

• Bio-2019-0124: ACE-536-L-LTFU-001: A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept (ACE-536) clinical trials”

• Bio-2021-0211: A Phase 3, Double-Blind, Randomized, Placebo- Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non- Transfusion Dependent Alpha or Beta-Thalassemia (ENERGIZE)

• Bio-2021-0222: A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)

• Bio-2021-0456: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease

• An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP420 in subjects with transfusion-dependent β-thalassemia (Pharmacosmos study)

• A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of FT-4202 in Patients with Thalassemia or Sickle Cell Disease (HEM-201 study)

• A Phase 2a, double-blind, randomised, placebo-controlled, efficacy, and safety study of multiple doses of VIT-2763(Vamifeport) in subjects with sickle cell disease (ViSion Serenity)

• A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease (rise up study)

• BIO-2023-0081/ACE-536-MF-002: A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (ACE-536-MF-002)

Ongoing Malignant Hematology clinical trials: 

PI: Dr. Jean el Cheikh:

• BIO-2023-0239: A randomized, controlled, open-label, phase III study evaluating Indolor vs Standard of Care in the prevention of transplant-related Oral Mucositis Post-hematopoietic stem cell transplantation at AUBMC

• BIO-2022-0145: A randomized, controlled, open-label, phase III study evaluating Flexitol® vs Standard of Care in the prevention and treatment of transplant-related acute cutaneous Graft-versus-Host-Disease (aGVHD) post-Allogenic hematopoietic stem cell transplantation (Allo-SCT) at AUBMC

PI: Dr. Ali Bazarbachi:

• BIO-2017-0420: A phase 3, Multicenter, Open-label Randomized Study of Oral ABL001 vs Bosutinib in patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors

   

• BIO-2018-0298: Randomized, Open-label, Phase II, Multicenter, Mutli-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myleiod Leukemia